可切除与交界可切除胰腺癌的新辅助治疗或直接手术:随机对照试验的荟萃分析
该系统检索比较可切除和交界可切除胰腺癌新辅助治疗与直接手术的随机试验,纳入7项试验共938例患者。新辅助治疗较直接手术改善总生存(HR 0.66,95%CI 0.52-0.85;P=0.001;I²=46%),中位总生存由19个月增至29个月。交界可切除亚组新辅助治疗改善总生存(HR 0.61,95%CI 0.44-0.85;P=0.004;I²=59%),可切除亚组无统计学显著差异(HR 0.77,95%CI 0.53-1.12;P=0.18;I²=20%)。
要点
- 新辅助治疗较直接手术改善可切除和交界可切除胰腺癌总生存(HR 0.66,95%CI 0.52-0.85;P=0.001;I²=46%)。
- 交界可切除亚组新辅助治疗改善总生存(HR 0.61,95%CI 0.44-0.85;P=0.004;I²=59%)。
- 可切除亚组总生存无统计学显著差异(HR 0.77,95%CI 0.53-1.12;P=0.18;I²=20%)。
核心结论
- 交界可切除胰腺癌患者新辅助治疗较直接手术改善总生存。
- 可切除胰腺癌患者新辅助治疗是否改善生存需更多证据。
研究设计与样本
- 系统检索建库至2020年12月发表的比较可切除和交界可切除胰腺癌新辅助治疗与直接手术的随机试验。
- 纳入7项试验共938例患者,主要结局为意向性治疗的总生存,按可切除状态进行亚组分析。
- 采用随机效应模型进行荟萃分析,采用GRADE方法评估证据确定性。
主要发现
- 所有试验均包含新辅助吉西他滨为基础的化(放)疗组,无研究使用辅助FOLFIRINOX。
- 新辅助治疗较直接手术改善总生存(HR 0.66,95%CI 0.52-0.85;P=0.001;I²=46%),中位总生存由19个月增至29个月。
- 可切除胰腺癌亚组(静脉接触≤180°、无动脉接触)总生存无统计学显著差异(HR 0.77,95%CI 0.53-1.12;P=0.18;I²=20%)。
- 交界可切除胰腺癌亚组(静脉接触>180°、任何动脉接触)新辅助治疗改善总生存(HR 0.61,95%CI 0.44-0.85;P=0.004;I²=59%)。
- 总生存结局的GRADE证据确定性为高。
关键数值与推荐
- 可切除胰腺癌定义:静脉接触≤180°、无动脉接触。
- 交界可切除胰腺癌定义:静脉接触>180°、任何动脉接触。
- 总生存结局GRADE证据确定性为高。
临床怎么用
- 作者认为交界可切除胰腺癌患者新辅助治疗较直接手术改善总生存。
- 作者认为可切除胰腺癌患者新辅助治疗是否改善生存需更多证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking. METHODS: We systematically searched for randomised trials comparing neoadjuvant therapy with upfront surgery for resectable and borderline resectable pancreatic cancer published since database inception until December 2020. The primary outcome was overall survival (OS) by intention-to-treat with subgroup analyses for resectability status. Meta-analyses using a random-effects model were performed. Certainty of evidence was assessed using the GRADE approach. RESULTS: Seven trials with 938 patients were included. All trials included a neoadjuvant gemcitabine-based chemo(radio)therapy arm. None of the studies used adjuvant FOLFIRINOX. Neoadjuvant therapy improved OS (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.52-0.85; P = 0.001; I2 = 46%) compared with upfront surgery. This represents an increase in median OS from 19 to 29 months. In the subgroup of resectable pancreatic cancer (i.e., venous contact ≤180°, no arterial contact), no statistically significant difference in OS was observed (HR 0.77, 95% CI 0.53-1.12; P = 0.18; I2 = 20%). In the subgroup of borderline resectable pancreatic cancer (i.e. venous contact >180°, any arterial contact), neoadjuvant therapy improved OS (HR 0.61, 95% CI 0.44-0.85; P = 0.004; I2 = 59%). The GRADE certainty of evidence was high for the outcome of OS. CONCLUSIONS: Neoadjuvant therapy improves OS compared with upfront surgery in patients with borderline resectable pancreatic cancer. More evidence is required on whether neoadjuvant therapy improves survival for patients with resectable pancreatic cancer.
引用
- van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2021. PMID: 34838371. doi:10.1016/j.ejca.2021.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。